Project-003

项目-003

• 批准号: 10817340
• 负责人: KUNLE O. ODUNSI
• 金额: $ 10.31万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10817340
• 关键词: Address; Biological Markers; Biostatistics Core; Cancer Center Support Grant; Cancer Patient; Chicago; Clinical; Clinical Drug Development; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Combined Modality Therapy; Comprehensive Cancer Center; Conduct Clinical Trials; Core Facility; Cyclic GMP; Development; Doctor of Philosophy; Faculty; Fostering; Funding; Genetic Markers; Goals; Grant; Hematologic Neoplasms; Human; Immunologic Monitoring; Immunotherapeutic agent; Infrastructure; Innovative Therapy; Investigational Therapies; Laboratories; Lead; Malignant Neoplasms; Medical Oncologist; Medicine; Mentored Clinical Scientist Development Program; Mentors; Mentorship; Molecular Target; Multi-Institutional Clinical Trial; Oncology; Pathway interactions; Patients; Peer Review; Pharmacogenomics; Pharmacology; Phase; Preclinical Drug Development; Prognostic Marker; Publications; Research; Research Personnel; Resource Sharing; Scientist; Solid Neoplasm; Testing; Therapeutic; Training; Translating; Translational Research; Translations; Treatment Efficacy; Treatment-related toxicity; United States National Institutes of Health; Universities; Work; anticancer research; arm; bench to bedside; cancer clinical trial; cancer therapy; career; career development; clinical biomarkers; clinical care; clinical practice; drug development; early phase trial; effective therapy; experience; human tissue; implementation efforts; innovation; interest; kinase inhibitor; member; molecular targeted therapies; next generation; novel; novel therapeutics; personalized cancer care; pre-clinical; preclinical study; predictive marker; programs; research to practice; tissue resource; translational pipeline; translational study

ABSTRACT The Clinical and Experimental Therapeutics (CET) Program is a cohesive, integrated group of 51 members representing nine different Departments. The overall goal of the Program is to foster interaction between basic and clinical investigators to develop innovative therapies for cancer patients. As the major clinical and translational arm of the UCCCC, the Program interfaces with all of the other Programs to seamlessly integrate fundamental cancer research with clinical care and clinical research objectives. The two co-leaders, M. Eileen Dolan, PhD, a laboratory-based scientist with experience in preclinical and translational studies, and Walter Stadler, MD, a medical oncologist with expertise in clinical trials and clinical drug development, have complementary expertise, and work well together to promote the goals of the CET Program. They jointly address Program-specific issues, including membership, funding, and scientific direction. Dr. Dolan is co-Pl of a T32 Clinical Therapeutics training grant and Dr. Stadler is co-Pl of an oncology Paul Calabresi K12 grant; therefore, they are also well integrated into the training and mentorship of fellows and junior faculty. Program members place an emphasis on translational and clinical research, as well as lead studies conducted by national cooperative groups to facilitate the development of new therapies for hematologic malignancies and solid tumors. The Program has a long-standing interest in all phases of clinical drug development from preclinical to early-phase trials to cooperative group led Phase Ill trials with a strong focus on pharmacogenomics and pharmacology. The specific scientific aims of the CET Program are to: 1) Pursue a broad Program of pharmacogenomic, molecular target, and biomarker research in the preclinical and clinical settings as well as to translate the findings into clinical practice; 2) Foster interactions between basic and clinical investigators that will result in innovative and effective therapies; 3) Integrate new drugs and immunotherapeutics into the development of multimodality therapies for patients with hematologic malignancies and advanced solid tumors; and 4) Train the next generation of leaders in clinical and translational research through formal mentoring and career development efforts. These scientific goals are achieved through programmatic efforts emphasizing three themes: pharmacogenomics, molecular targets, and biomarkers through preclinical and clinical studies. Program members are supported by $21,333,004 in total funding (DC), with $7,712,492 in peer-reviewed funding ($5,380,171 from NCI), and $13,620,512 in non-peer-reviewed support. For the 2013-2016 period, Program members have 888 peer-reviewed publications, with 20% interprogrammatic, 28% intraprogrammatic, and 9% both intra- and interprogrammatic.

摘要 临床和实验治疗学（CET）计划是一个由51名成员组成的有凝聚力的综合小组 代表九个不同的部门该计划的总体目标是促进基本 和临床研究人员为癌症患者开发创新疗法。作为主要的临床和 作为UCCCC的一个翻译分支，该计划与所有其他计划接口， 具有临床护理和临床研究目标的基础癌症研究。两位领导人，M。Eileen Dolan博士，一位在临床前和转化研究方面具有经验的实验室科学家，以及Walter Stadler博士是一位在临床试验和临床药物开发方面具有专业知识的医学肿瘤学家， 互补的专业知识，并共同努力，以促进CET计划的目标。他们共同 解决方案的具体问题，包括成员，资金和科学方向。多兰博士是 T32临床治疗培训补助金和Stadler博士是肿瘤学Paul Calabresi K12补助金的共同Pl; 因此，他们也很好地融入了研究员和初级教员的培训和指导。程序 成员们强调转化和临床研究，以及由 国家合作小组，以促进血液恶性肿瘤新疗法的开发， 实体瘤该计划对临床药物开发的所有阶段都有长期的兴趣， 从临床前试验到早期试验，再到合作小组领导的III期试验，重点关注 药物基因组学和药理学。CET计划的具体科学目标是： 1)在临床前研究中开展广泛的药物基因组学、分子靶点和生物标志物研究项目 和临床环境，以及将研究结果转化为临床实践; 2）促进 基础和临床研究人员，将导致创新和有效的治疗; 3）整合新药， 免疫疗法用于血液病患者的多模式疗法的开发 恶性肿瘤和晚期实体瘤; 4）培养下一代临床和 通过正式的指导和职业发展努力进行转化研究。这些科学目标是 通过强调三个主题的计划性努力实现：药物基因组学，分子靶点， 生物标志物通过临床前和临床研究。计划成员总共获得21，333，004美元的支持 资金（DC），同行评审资金7，712，492美元（NCI 5，380，171美元），非同行评审资金13，620，512美元 支持.在2013-2016年期间，计划成员有888篇同行评审的出版物， 20%跨方案，28%方案内，9%方案内和方案间。